Skip to main content
ANGLE PLC logo

ANGLE PLC — Investor Relations & Filings

Ticker · AGL ISIN · GB0034330679 LEI · 213800BY11K6W3NMS374 IL Human health and social work activities
Open in API
Filings indexed 488 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country GB United Kingdom
Listing IL AGL

About ANGLE PLC

https://angleplc.com/

ANGLE PLC is a liquid biopsy company that has developed the proprietary Parsortix® system for cancer diagnostics and research. The system uses a patented, size-based microfluidic technology to capture and harvest intact, live circulating tumor cells (CTCs) and CTC clusters from patient blood for downstream analysis. The company's commercial offerings are focused on two main areas: diagnostic products and clinical services. Products include the FDA-cleared, automated Parsortix PC1 instrument and its associated single-use cassettes for use in clinical laboratories. The company also provides global laboratory services from its GCP-compliant facilities, supporting biopharmaceutical companies and translational research projects with complete CTC harvesting and analysis solutions. These applications aid in drug development, patient monitoring, and the advancement of personalized medicine in oncology.

Recent filings

Filing Released Lang Actions
Collaboration with AdventHealth for two studies
Regulatory Filings Classification · 85% confidence The document is an RNS press release announcing a corporate collaboration for clinical studies, with no financial results, governance changes, or regulatory report content. It does not fit specific categories like earnings, M&A, or management changes. As a general announcement distributed via the London Stock Exchange’s RNS system, it falls under Regulatory Filings (RNS).
2026-05-18 English
Q1 trading update and outlook for 2026
Earnings Release Classification · 80% confidence The document is an RNS regulatory news announcement providing a Q1 trading update and outlook for FY 2026. It contains key highlights of operating and financial performance (cost savings, cash position, pipeline expectations) but is not a full interim report with detailed financial statements. This matches the “Earnings Release (ER)” category as an initial announcement of quarterly/periodical financial results. It is not a complete interim report (IR), nor simply an announcement of a report (RPA), nor a management change, M&A, or other category. Q1 2026
2026-05-11 English
Confirmation of Q1 trading update
Regulatory Filings Classification · 95% confidence The document is a short announcement from CelLBxHealth plc dated 30 April 2026, confirming that a Q1 trading update will be provided in mid-May. It does not contain any actual financial data or detailed financial statements. The text is under 5,000 characters and primarily serves as a notice about an upcoming report rather than the report itself. There are no indications of it being a full quarterly report, earnings release, or any other detailed financial filing. Therefore, it fits the criteria of a Regulatory Filing (RNS) as a general announcement that does not fit into more specific categories.
2026-04-30 English
Research Collaboration with The Royal Marsden
Regulatory Filings Classification · 85% confidence The document is an RNS announcement (Regulatory News Service) distributed via the London Stock Exchange’s Primary Information Provider. It describes a research collaboration with The Royal Marsden NHS Foundation Trust, contains no financial results, management changes, dividend notices, or other specialized filings (e.g., earnings release, board changes, M&A, share issues, etc.). It is a general regulatory announcement of corporate news. Therefore it falls under the fallback category “Regulatory Filings (RNS).”
2026-04-20 English
Aligning Regulatory Approach with Commercial Needs
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from CelLBxHealth plc regarding a strategic decision to discontinue maintenance of its FDA establishment license and device listing for a product. It discusses operational and commercial priorities, cost discipline, and regulatory strategy alignment. The text is an official company announcement distributed via the Regulatory News Service (RNS) and does not contain financial statements, detailed financial data, or comprehensive report content. It is not a full annual or interim report, audit report, earnings release, or any other detailed financial or management report. The document is a regulatory announcement informing the market about a change in regulatory status and business strategy, fitting the definition of a Regulatory Filing (RNS). The document length (5544 characters) and content confirm it is not merely a brief report publication announcement but a substantive regulatory update. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-02-13 English
Preliminary Fourth Quarter 2025 Financial Results
Earnings Release Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from CelLBxHealth plc providing preliminary, unaudited financial results for the fourth quarter and full year 2025. It includes key financial highlights (revenue, cash position), operational updates (cost rationalization, delisting from OTCQX), and forward-looking statements. Because it is an initial announcement of financial results containing key highlights rather than the full audited annual report, it is classified as an Earnings Release (ER). Q4 2025
2026-01-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.